Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,417
datasets available to search
ShareScore release 0.9.0
Dataset results
1,417 results for “triple negative breast cancer”
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
ClinicalTrials.gov study NCT02101385. IPD Sharing: NO. Countries: 1. Publications: 2.
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-P
ClinicalTrials.gov study NCT03337724. IPD Sharing: Not stated. Countries: 30. Publications: 1.
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)
ClinicalTrials.gov study NCT03167619. IPD Sharing: NO. Countries: 1. Publications: 1.
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
ClinicalTrials.gov study NCT02530489. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
ClinicalTrials.gov study NCT00483223. IPD Sharing: NO. Countries: 1. Publications: 1.
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
ClinicalTrials.gov study NCT01074970. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
ClinicalTrials.gov study NCT03901469. IPD Sharing: NO. Countries: 4. Publications: 1.
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK
ClinicalTrials.gov study NCT04191135. IPD Sharing: YES. Countries: 15. Publications: 0.
Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients
ClinicalTrials.gov study NCT02027376. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT04111510. IPD Sharing: Not stated. Countries: 1. Publications: 1.
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT03193853. IPD Sharing: YES. Countries: 1. Publications: 1.
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
ClinicalTrials.gov study NCT02124902. IPD Sharing: NO. Countries: 1. Publications: 1.
Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment
ClinicalTrials.gov study NCT06497322. IPD Sharing: YES. Countries: 1. Publications: 8.
Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
ClinicalTrials.gov study NCT02402764. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
ClinicalTrials.gov study NCT01982448. IPD Sharing: NO. Countries: 1. Publications: 2.
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer
ClinicalTrials.gov study NCT02370238. IPD Sharing: NO. Countries: 7. Publications: 2.
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
ClinicalTrials.gov study NCT00528567. IPD Sharing: Not stated. Countries: 40. Publications: 2.
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
ClinicalTrials.gov study NCT02648477. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
ClinicalTrials.gov study NCT02158507. IPD Sharing: NO. Countries: 1. Publications: 1.
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
ClinicalTrials.gov study NCT02657889. IPD Sharing: NO. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.